Participant-centric study design has advanced, but site-centric execution has not kept pace. In the Journal for Clinical Studies, Brian Mallon examines how unclear expectations, administrative burden and contract delays ...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Banyan BioInnovations launces with ICON support
$100M Biotech investment fund announces collaboration with ICON designed to improve trial execution and design, as well as commercialisation strategy.
-
Banyan BioInnovations debuts with $100M+ and ICON
A new biotech investment firm launches with more than $100 million in initial commitments from life science investors. ICON is both a strategic collaborator and an equity investor.
-
Overcoming Formulation Challenges for Biosimilars
Media article discussing how high-concentration formulations and patient centricity are challenges to the formulation of biosimilars, which already face patent protection barriers.
-
Recentring sites: The human factors slowing study start-up and how to resolve them
In the Journal for Clinical Studies article, Brian Mallon explores the human factors slowing study start‑up and outlines how a more site‑centred approach can accelerate activation, recruitment and retention.
-
Partnership set to make therapies ‘reach patients sooner’
ICON's partnership with Advarra will integrate ICON’s global clinical trial solutions and services with Advarra’s site CTMSs, eISF, and eSource systems, which are already used by more than 50,000 investigators worldwide, including researchers at 90 of the top 125 academic medical centres.
-
From study end to long-term insight: Choosing the right vaccine follow-up strategy
Navigating long‑term vaccine follow‑up isn’t one‑size‑fits‑all; explore the key questions that help determine the right mix of traditional studies and tokenisation.
-
ICON teams with Advarra for integrated, AI-driven site network
ICON and Advarra partnership creates an integrated site-centric system that tackles operational bottlenecks and simplifies study execution, addressing sponsors most pressing challenges.
-
ICON, Advarra partnership aims to optimize trials, expand access
ICON and Advarra have partnered to create a connected network of clinical trial sites that integrates ICON’s global trial solutions with Advarra’s site technologies, aiming to streamline study operations, boost efficiency, and expand trial access.
-
ICON partners with Advarra to launch connected site network model
ICON and Advarra have formed a partnership to create a connected, research ready site network that integrates ICON’s clinical trial services with Advarra’s site-facing technology to streamline study startup and trial execution. The collaboration aims to reduce administrative burden, enhance operational visibility, and broaden trial access by standardising workflows for both established and emerging research sites.
-
ICON, Advarra partner on connected site network model
ICON plc and Advarra, a provider of connected, intelligence-powered research technology, have entered a partnership agreement to introduce a new ‘research-ready,’ connected site network model for clinical trials.
